Biosimilars mean competition for biologics

Document Sample
Biosimilars mean competition for biologics Powered By Docstoc
					IN FOCUS

Biosimilars mean competition for biologics
When patents expire o
				
DOCUMENT INFO
Description: When patents expire on brands like Merck's cholesterol pill Zocor, million-dollar ad budgets usually fizzle as cheap generic competition takes over the market. Experts say the situation will be different once biologic brands face competition from follow-on biologics (FOB) in the US. Far from sapping promotional dollars like small-molecule generics, biosimilars could spur marketing by makers of follow-ons and original biologics alike. The passage of healthcare reform, including an approval pathway for biosimilars, means biologic brands could see rivals replicate and market similar products. The legislation lays out a series of requirements for the FDA to consider FOB applications. Higher manufacturing costs will be built into biogenerics pricing.
BUY THIS DOCUMENT NOW PRICE: $6.95 100% MONEY BACK GUARANTEED
PARTNER ProQuest LLC
ProQuest creates specialized information resources and technologies that propel successful research, discovery, and lifelong learning.